1. Harris MI, Flegal KM, Cowie CC, et. al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21(4):518-24, 1998.



2. Gregg EW, Engelgau MM, Narayan V. Complications of diabetes in elderly people. BMJ 325:916-917, 2002.



3. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414-31, 1998.



4. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for Improving the Care of the Older Person with Diabetes Mellitus. JAGS 51:S265-S280, 2003.



5. American Diabetes Association. Clinical Practice Recommendations 2008. Diabetes Care 31(Supp1):S55-60, 2008.



6. Ibid; pages S12-54.



7. Bertoni, AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related Morbidity and Mortality in a National Sample of U.S. Elders. Diabetes Care 25:471-475, 2002.



8. Gregg EW, Yaffe K, Cauley JA, et al. Is Diabetes Associated with Cognitive Impairment and Cognitive Decline Among Older Women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160:174-180, 2000.



9. Feil D, Unutzer J. Cognitive impairment, chronic medical illness, and risk of mortality in an elderly cohort. Am J Geriatr Psych 11:551-560, 2003.



10. Tinetti ME, Williams TF, Mayewski R. Fall Risk Index for Elderly Patients Based on Number of Chronic Disabilities. Am J Med 80:429-434, 1986.



11. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998.



12. Selvin E et al. The Burden and Treatment of Diabetes in Elderly Individuals in the U.S., Diabetes Care 21(11):2415-9, 2006.



13. Olson D, Norris S. Diabetes in older adults: Overview of the AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics 59:18-24, 2004.



14. Sakharova O, Inzucchi S. Treatment of diabetes in the elderly: Addressing its complexities in this high-risk group. Postgraduate medicine 119:19-29, 2005.



15. Riddle MC and Drucker DJ. Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1. Diabetes Care 29:535-49, 2006.



16. Bailey CJ, Turner RC. Metformin. N Engl J Med 334:574-9, 1996.



17. Inzucchi S. Oral Anti-hyperglycemic Therapy for Type 2 Diabetes: Scientific Review. JAMA 287:360-372, 2002.



18. Drucker D, Easley C, Kirkpatrick P. Sitagliptin. Nat Rev Drug Dis 6:109-110, 2007.



19. Keating G. Exenatide. Drugs 65(12):1681-1692, 2005.



20. Riddle M et al. Treat to Target. Diabetes Care 26:3080-3086, 2003.



21. Rave. Advantage of Premeal Injected Insulin Glulisine Compared with Regular Human Insulin in Subjects with Type 1 Diabetes. Diabetes Care 29(8):1812-1817, 2006.



22. David M. Nathan, John B. Buse, Mayer B. Davidson, Robert J. Heine, Rury R. Holman, Robert Sherwin, and Bernard Zinman. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972, 2006.



23. Nateglinide. The Medical Letter. 43(1101): 27-30.



24. Kahn S, et al. for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med 355:2427-2443, 2006.



25. Nissen S, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. NEJM 356(24):2457-2471, 2007.



26. Schwartz A, et al. Health, Aging and Body Composition (Health ABC) Study, Thiazolidinedione Use and Bone Loss in Older Diabetic Adults. J Clin Endocrinol Metab 91(9):3349-3354, 2006.



27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.



28. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKDPS 38. BMJ 318:703-13, 1998.



29. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized trial. Lancet 361:2005-16, 2003.